RANI THERAPEUTICS HOLDINGS-A (RANI) Fundamental Analysis & Valuation

NASDAQ:RANI • US7530181004

1.37 USD
+0.04 (+3.01%)
At close: Mar 11, 2026
1.3412 USD
-0.03 (-2.1%)
After Hours: 3/11/2026, 8:21:17 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RANI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to RANI. RANI was compared to 193 industry peers in the Pharmaceuticals industry. RANI has a bad profitability rating. Also its financial health evaluation is rather negative. RANI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. RANI Profitability Analysis

1.1 Basic Checks

  • RANI had negative earnings in the past year.
  • RANI had a negative operating cash flow in the past year.
  • RANI had negative earnings in each of the past 5 years.
  • In the past 5 years RANI always reported negative operating cash flow.
RANI Yearly Net Income VS EBIT VS OCF VS FCFRANI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -279.27%, RANI is doing worse than 90.67% of the companies in the same industry.
Industry RankSector Rank
ROA -279.27%
ROE N/A
ROIC N/A
ROA(3y)-56.31%
ROA(5y)-39.33%
ROE(3y)-617.95%
ROE(5y)-378.96%
ROIC(3y)N/A
ROIC(5y)N/A
RANI Yearly ROA, ROE, ROICRANI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RANI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RANI Yearly Profit, Operating, Gross MarginsRANI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. RANI Health Analysis

2.1 Basic Checks

  • RANI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RANI has been increased compared to 1 year ago.
  • Compared to 5 years ago, RANI has more shares outstanding
  • RANI has a worse debt/assets ratio than last year.
RANI Yearly Shares OutstandingRANI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
RANI Yearly Total Debt VS Total AssetsRANI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • RANI has an Altman-Z score of -26.41. This is a bad value and indicates that RANI is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -26.41, RANI is not doing good in the industry: 86.01% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -26.41
ROIC/WACCN/A
WACC10.33%
RANI Yearly LT Debt VS Equity VS FCFRANI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • A Current Ratio of 0.26 indicates that RANI may have some problems paying its short term obligations.
  • RANI has a worse Current ratio (0.26) than 92.75% of its industry peers.
  • A Quick Ratio of 0.26 indicates that RANI may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.26, RANI is doing worse than 91.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.26
Quick Ratio 0.26
RANI Yearly Current Assets VS Current LiabilitesRANI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. RANI Growth Analysis

3.1 Past

  • RANI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.47%, which is quite impressive.
  • The Revenue has been growing slightly by 0.96% on average over the past years.
EPS 1Y (TTM)25.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-27.7%
Revenue growth 5Y0.96%
Sales Q2Q%N/A

3.2 Future

  • RANI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.47% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y56.7%
EPS Next 2Y31.92%
EPS Next 3Y20%
EPS Next 5Y9.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RANI Yearly Revenue VS EstimatesRANI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
RANI Yearly EPS VS EstimatesRANI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. RANI Valuation Analysis

4.1 Price/Earnings Ratio

  • RANI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year RANI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RANI Price Earnings VS Forward Price EarningsRANI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RANI Per share dataRANI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • RANI's earnings are expected to grow with 20.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.92%
EPS Next 3Y20%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RANI Dividend Analysis

5.1 Amount

  • No dividends for RANI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RANI Fundamentals: All Metrics, Ratios and Statistics

RANI THERAPEUTICS HOLDINGS-A

NASDAQ:RANI (3/11/2026, 8:21:17 PM)

After market: 1.3412 -0.03 (-2.1%)

1.37

+0.04 (+3.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-25
Inst Owners47.89%
Inst Owner Change850.26%
Ins Owners3.07%
Ins Owner Change58.69%
Market Cap166.48M
Revenue(TTM)1.20M
Net Income(TTM)-28.32M
Analysts82.22
Price Target9.44 (589.05%)
Short Float %12.6%
Short Ratio9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.06%
Min EPS beat(2)4.61%
Max EPS beat(2)9.5%
EPS beat(4)2
Avg EPS beat(4)0.18%
Min EPS beat(4)-7.31%
Max EPS beat(4)9.5%
EPS beat(8)5
Avg EPS beat(8)0.91%
EPS beat(12)9
Avg EPS beat(12)3.69%
EPS beat(16)13
Avg EPS beat(16)14.12%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)7.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 138.74
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.01
BVpS-0.06
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -279.27%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.31%
ROA(5y)-39.33%
ROE(3y)-617.95%
ROE(5y)-378.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.14%
Cap/Sales 9.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.26
Quick Ratio 0.26
Altman-Z -26.41
F-Score4
WACC10.33%
ROIC/WACCN/A
Cap/Depr(3y)156.71%
Cap/Depr(5y)155.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y56.7%
EPS Next 2Y31.92%
EPS Next 3Y20%
EPS Next 5Y9.47%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-27.7%
Revenue growth 5Y0.96%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.88%
EBIT Next 3Y-5.54%
EBIT Next 5Y14.98%
FCF growth 1Y49.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.19%
OCF growth 3YN/A
OCF growth 5YN/A

RANI THERAPEUTICS HOLDINGS-A / RANI FAQ

Can you provide the ChartMill fundamental rating for RANI THERAPEUTICS HOLDINGS-A?

ChartMill assigns a fundamental rating of 1 / 10 to RANI.


What is the valuation status of RANI THERAPEUTICS HOLDINGS-A (RANI) stock?

ChartMill assigns a valuation rating of 1 / 10 to RANI THERAPEUTICS HOLDINGS-A (RANI). This can be considered as Overvalued.


Can you provide the profitability details for RANI THERAPEUTICS HOLDINGS-A?

RANI THERAPEUTICS HOLDINGS-A (RANI) has a profitability rating of 0 / 10.


Can you provide the financial health for RANI stock?

The financial health rating of RANI THERAPEUTICS HOLDINGS-A (RANI) is 0 / 10.